



14th September 2023

National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051

Dear Sir/Madam,

**Sub.: Increase in volume
Scrip Code: AJANTPHARM**

We refer to your letter Ref. No.: NSE/CM/Surveillance/13400 dated September 13, 2023 sent by e-mail seeking clarification w.r.t. increase in volume of securities of our Company across Stock Exchanges.

In this regard we hereby clarify that as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we have timely disclosed to the Exchanges all the information/events that have a bearing on the operations/performance of the Company and no such material information/event have remained to be disclosed.

Significant increase in the volume of securities of the Company is purely driven by market dynamics. We do not know whether there is any connection of this to one news article published by BQ Prime citing report of Motilal Oswal Financial Services to the investors today. All the information mentioned in the said news article about our company is already in the public domain. Link of the news article is:

<https://www.bqprime.com/markets/ajanta-pharma-shares-at-all-time-high-after-august-sales-data>.

The Company has always abided by and complied with all the disclosures and regulatory requirements and has meticulously followed all the Corporate Governance norms.

We hope the above clarifies the position.

Yours Faithfully,

Gaurang Shah

VP – Legal & Company Secretary

